Analyst Price Targets — NVCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 18, 2026 2:59 pm | Emily Bodnar | H.C. Wainwright | $46.00 | $14.57 | TheFly | Novocure price target lowered to $46 from $48 at H.C. Wainwright |
| February 12, 2026 11:04 am | — | H.C. Wainwright | $47.00 | $13.74 | TheFly | Novocure price target raised to $47 from $39 at H.C. Wainwright |
| January 13, 2026 11:03 am | — | H.C. Wainwright | $39.00 | $14.18 | TheFly | Novocure price target lowered to $39 from $42 at H.C. Wainwright |
| January 5, 2026 2:54 pm | — | Evercore ISI | $20.00 | $13.71 | TheFly | Novocure price target lowered to $20 from $22 at Evercore ISI |
| October 30, 2025 4:11 pm | — | H.C. Wainwright | $42.00 | $13.18 | TheFly | Novocure price target raised to $42 from $38 at H.C. Wainwright |
| July 24, 2025 8:09 pm | Larry Biegelsen | Wells Fargo | $14.50 | $12.54 | TheFly | Novocure downgraded to Equal Weight from Overweight at Wells Fargo |
| December 2, 2024 11:00 am | Vijay Kumar | Evercore ISI | $30.00 | $26.43 | StreetInsider | Evercore ISI Upgrades NovoCure Ltd. (NVCR) to Outperform 'into Panova readout on asymmetric risk/reward' |
| October 16, 2024 6:06 am | Emily Bodnar | H.C. Wainwright | $30.00 | $17.78 | StreetInsider | H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy |
| July 26, 2024 6:48 am | Emily Bodnar | H.C. Wainwright | $24.00 | $18.26 | StreetInsider | NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright |
| May 3, 2024 6:46 am | Emily Bodnar | H.C. Wainwright | $22.00 | $14.19 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $22 at H.C. Wainwright |
Latest News for NVCR
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio,…
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.